Skip to content
Search

Latest Stories

Palexia oral solution recalled due to potential microbial contamination

Pb Staff writer
By Pb Staff writerFeb 09, 2021
Pb Staff writer
See Full Bio

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a recall alert for Palexia 20mg/ml oral solution.

The drug manufacturer Grünenthal Ltd has alerted of a potential microbial contamination during routine stability testing for the batches listed in the recall. Due to the detection of possible Burkholderia contaminans the batches listed below are being recalled as a precautionary measure.

Burkholderia contaminans is a gram-negative bacterium and any potential infection may be more serious for immunocompromised patients and patients suffering from cystic fibrosis.

This recall affects all batches of oral solution in the UK market that are still within their expiry date.

Batch NumberExpiry DatePack SizeFirst Distributed
00203N02.20221 x 200ml12.02.2018
00608N02.20221 x 200ml15.05.2018
00797N02.20221 x 200ml18.09.2018
01541l02.20221 x 100ml18.12.2017
00201N02.20221 x 100ml12.02.2018
00605N02.20221 x 100ml15.05.2018
00607N02.20221 x 100ml02.07.2018
01111N02.20221 x 100ml28.09.2018
01568N04.20221 x 100ml14.01.2019
00966P04.20241 x 100ml17.09.2019
01242P04.20241 x 100ml30.10.2019
01230P06.20241 x 100ml30.10.2019
01416P06.20241 x 100ml07.01.2020
00448R01.20251 x 100ml16.04.2020
01104R02.20251 x 100ml12.10.2020
01631R09.20251 x 100ml16.12.2020

This medicine is intended for acute pain situations. Whilst the product has a five-year shelf-life unopened, the bottle(s), once opened, should be used within six weeks.

Community pharmacists have been suggested to stop supplying the affected batches immediately and quarantine all remaining stock to return it to the concerned supplier.

Pharmacists should contact all patients who have been dispensed this product between December 2017 to February 2021 to determine if any patients have the affected batches within their possession and to return these to the pharmacy as part of this recall.

“If patients are confirmed to have the bottle(s) from the affected batches in their possession and they are currently administering dose, they should be signposted to this alert and informed to immediately contact their GP/prescriber to consider withdrawal of the product, tapering of the dose and any suitable clinical alternatives,” the MHRA said.

Related News

New professional liability insurance policy for RPS members launched
News

RPS launches professional liability insurance for members

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling
News

Pharma imports to US surged in March as drugmakers look to avoid tariffs

WW International logo with bold bankruptcy notice and confident recovery statement

US diet company WeightWatchers files for bankruptcy

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc